Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2




Bayer Yanks Aprotinin off the Market Pending Analysis of BART
Link ID 337
Title Bayer Yanks Aprotinin off the Market Pending Analysis of BART
Url http://www.medscape.com/viewarticle/565339?src=rss
Description The company says the marketing suspension is "temporary" pending a full analysis of the trial, which pointed to higher rates of 30-day mortality among high-risk surgery patients randomized to aprotinin. Medscape Medical News
Category Articles > Business of Medicine
Keywords
Date Nov 6, 2007
Contact Name
Email
Write a Review   Add to My Favorite   Refer it to Friend   Report Broken Link  

Average Visitor Rating: 0.00 (out of 5)
Number of ratings: 0 Votes
Visitor Rating

 Other links at Articles > Business of Medicine
1. FDA Advisers Back Stronger Flu Drug Warnings
  U.S health advisers recommended on Tuesday stronger warnings on the labels of flu drugs made by Roche Holding AG and GlaxoSmithKline Plc, amid reports of abnormal and, in the case of the Roche drug, sometimes fatal psychiatric behavior. Reuters Health Information
Category:   Articles > Business of Medicine


2. Cigna Fourth-Quarter Profit Rises 13 Percent
  Insurer Cigna Corp said on Wednesday that fourth-quarter profit rose 13 percent, as its international operations and disability and life segment offset weaker performance in its main health care business. Reuters Health Information
Category:   Articles > Business of Medicine


3. No HOPE Without Proof: Do ARBs Meet the Standard for Cardiovascular Protection?
  RAS blockade by ACEIs or ARBs is of proven benefit for cardiovascular disease, but whether either is superior to their combination is unknown. Evidence will be available in 2008 from ONTARGET trial.
The Medscape Journal of Medicine
Category:   Articles > Business of Medicine


4. New Gout Drug Gets FDA Panel Nod
  Uloric has been recommended for FDA approval and may be the first new gout drug approved in 40 years. WebMD Health News
Category:   Articles > Business of Medicine


5. Publication Bias and the Pharmaceutical Industry: The Case of Lamotrigine in Bipolar Disorder
  Negative unpublished data on lamotrigine provide an important context for clinical practice and research and raise concerns about access to studies showing inefficacy of psychotropic medications.
The Medscape Journal of Medicine
Category:   Articles > Business of Medicine




Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS